These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 3884319)

  • 1. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Brogden RN
    Drugs; 1985 Feb; 29(2):105-61. PubMed ID: 3884319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Heel RC
    Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.
    Richards DM; Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1984 Jun; 27(6):469-527. PubMed ID: 6329638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Brogden RN; Heel RC
    Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime.
    Gentry LO
    Pharmacotherapy; 1985; 5(5):254-67. PubMed ID: 3906585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Bryson HM
    Drugs; 1994 Mar; 47(3):471-505. PubMed ID: 7514976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Holmes B; Richards DM; Brogden RN; Heel RC
    Drugs; 1984 Nov; 28(5):375-425. PubMed ID: 6391888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Carmine AA; Brogden RN; Heel RC; Romankiewicz JA; Speight TM; Avery GS
    Drugs; 1983 Oct; 26(4):279-333. PubMed ID: 6354685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.
    Carmine AA; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Mar; 25(3):223-89. PubMed ID: 6303743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
    Mawal Y; Critchley IA; Riccobene TA; Talley AK
    Expert Rev Clin Pharmacol; 2015; 8(6):691-707. PubMed ID: 26420166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Ward A; Richards DM
    Drugs; 1985 Nov; 30(5):382-426. PubMed ID: 3905336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections.
    Holloway WJ; Palmer D
    Am J Med; 1996 Jun; 100(6A):52S-59S. PubMed ID: 8678098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections.
    Hoepelman AI; Kieft H; Aoun M; Kosmidis J; Strand T; Verhoef J; Gillespie SH; Riddell J; Varghese G; Meunier F
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():175-86. PubMed ID: 8150761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefsulodin and ceftazidime, two antipseudomonal cephalosporins.
    Smith BR
    Clin Pharm; 1984; 3(4):373-85. PubMed ID: 6380902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
    Rains CP; Bryson HM; Peters DH
    Drugs; 1995 Apr; 49(4):577-617. PubMed ID: 7789291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biological bases for the use of ceftazidime in anti-infection therapy].
    Bergogne-Berezin E
    Rev Med Interne; 1986 Nov; 7(5):477-85. PubMed ID: 3544115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.